Fig. 3
From: Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy
Schematic illustration of various inorganic, organic, and hybrid porous nanomaterials (PNMs) for tumor therapy. Inorganic PNMs include: H-MnO2-PEG [73], OX/IND-MSNP [55], PMSN@OVA-MPN [58], CuS@mSiO2-PFP-PEG [75]; organic PNMs include: COF@ICG@OVA 109], COF-609 + αCD47 [80]; hybrid PNMs include: Hf-DBP/αCD47 [98], IDOi@Hf-TBC [4], MOF-S-S-OVA@CpG [100], NV-ZIF [94], ZANPs [99], Hf12-DBA [96]. PNMs can achieve the combination of cancer immunotherapy with PDT, PTT, CT, and RT for better cancer treatment outcomes